Authors
Latest:
Dr. Balmanoukian on Immunotherapy Advancements in GU CancersAni Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.
Latest:
Dr. Balmanoukian on Clinical Trials With Immunotherapy in GU CancersAni S. Balmanoukian, MD, director of Thoracic Oncology, and associate director of the Phase I Immune-Oncology Program at The Angeles Clinic and Research Institute, discusses the importance of clinical trials investigating immunotherapy for patients with genitourinary (GU) cancers.
Latest:
Dr. Hamid on Potential Combinations With Docetaxel in mHSPC SubtypesAnis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.
Latest:
Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLCThe treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.
Latest:
New Strategies for Targeting CTLA-4 EmergeIn 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.
Latest:
Acute Myeloid Leukemia: Updates From The ASH 2022 Annual MeetingShared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.
Latest:
Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic CancersAnkit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.
Latest:
Dr. Klopp on the Future of Chemoradiation in Endometrial CancerAnn H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.
Latest:
Dr Partridge on Breast Cancer Recurrence in Young Breast Cancer SurvivorsAnn H. Partridge, MD, MPH, discusses the incidence of second primary breast cancer in young patients with a history of breast cancer.
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin ComboAnn LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.
Latest:
Dr. Cheng on the Need For Biomarkers in HCCAnn-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.
Latest:
Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical TrialsAnn-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.
Latest:
Dr. Beddoe on the Impact of Cervical Cancer ScreeningAnn Marie Beddoe, MD, assistant professor of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital, discusses the impact of cervical cancer screening for women in the United States.
Latest:
Navigating Breast Cancer Survivorship: Sustaining the Good NewsForty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.
Latest:
Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating AgentsErythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase
Latest:
UVA Screening Program Seeks to Get Ahead of Colorectal CancerApproximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.
Latest:
Dr. LaCasce Discusses the FDA Approval of Lenalidomide/Rituximab in Non-Hodgkin LymphomaAnn S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses the FDA approval of lenalidomide (Revlimid) and rituximab (Rituxan; R2) in non-Hodgkin lymphoma.
Latest:
The Search for Immune-Specific Biomarkers Is in Full SwingAn improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.
Latest:
Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast CancerOncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.
Latest:
Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma TherapyA 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.
Latest:
Dr. Ferrari on LBH589 and Bicalutamide in CRPCAnna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.
Latest:
Closing Thoughts on Intralesional Therapy for Melanoma and CSCCA panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.
Latest:
Dr. Farago on Frontline Immunotherapy Versus Maintenance Immunotherapy in SCLCAnna F. Farago, MD, PhD, medical oncologist at the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the use of frontline immunotherapy versus maintenance immunotherapy in patients with small cell lung cancer (SCLC).
Latest:
Dr. Farago on Opportunities to Investigate Biomarkers for Small Cell Lung CancerAnna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).
Latest:
Palliative Care: Let’s Keep the Conversation OpenAs the end of my hematology/oncology fellowship draws near, I am reminded every day that oncology is not about winning or losing.
